Trade Summary

Yesterday, TABUTEAU HERRIOT, serving as Chief Executive Officer at Axsome Therapeutics, Inc. (AXSM), sold 49,670 shares at $241.01 per share, for a total transaction value of $11,970,966.70. Following this transaction, TABUTEAU HERRIOT now holds 7,229 shares of AXSM.

This sale represents a 87.30% decrease in TABUTEAU HERRIOT's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, June 9, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, June 9, 2026 at 5:17 PM ET, meaning the disclosure happened on the same day as the trade.

Axsome Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.